David A. Kleiman, Matthew J. Sporn, Toni Beninato, Michael J. Crowley, Anvy Nguyen, Alessia Uccelli, Theresa Scognamiglio, Rasa Zarnegar and Thomas J. Fahey III Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules Cancer 119
Version of Record online: 21 DEC 2012 | DOI: 10.1002/cncr.27888
The B-type Raf kinase Val600Glu mutation, or BRAF(V600E), is most common in indeterminate thyroid nodules with other cytologic risk factors for malignancy which already warrant a total thyroidectomy. Therefore, single mutation screening for BRAF(V600E) does not meaningfully improve preoperative risk stratification and is unlikely to alter the initial management of patients with indeterminate nodules.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field